By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boston Therapeutics, Inc. 

1750 Elm Street, Suite 103

Manchester  New Hampshire  03104  U.S.A.
Phone: 603-935-9799 Fax: 603-685-4784



Company News
Boston Therapeutics, Inc. Reports Second Quarter Results And Provides Corporate Update 8/14/2015 10:37:22 AM
Boston Therapeutics, Inc. Nominates Philip Getter To Board Of Directors 8/6/2015 10:03:56 AM
Boston Therapeutics, Inc. ' Hong Kong Affiliate Advance Pharmaceutical's BTI-320 Clinical Trial Reaches Mid-Point By Enrolling 30 Patients At The Chinese University Of Hong Kong 7/8/2015 10:46:59 AM
Boston Therapeutics, Inc. Presents Findings Of BTI-320, A Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate As Therapy To Manage Blood Glucose At 75th Annual Meeting Of The American Diabetes Association 6/9/2015 11:09:39 AM
Boston Therapeutics, Inc. & University at Buffalo's Translational Pharmacology Research Core Initiates BTI-320 Clinical Trials Alliance In Buffalo, NY And NYC's Chinatown 5/28/2015 10:52:54 AM
Boston Therapeutics, Inc. Reports First Quarter Results And Provides Corporate Update 5/21/2015 12:19:14 PM
Boston Therapeutics, Inc. Announces Fourth Quarter And Fiscal Year 2014 Financial Results And Provides Corporate Update 3/31/2015 11:49:03 AM
Boston Therapeutics, Inc. ' Affiliate Advanced Pharmaceutical Initiates SUGARDOWN(R) Clinical Trial In Hong Kong 3/25/2015 11:53:44 AM
Boston Therapeutics, Inc. And Advance Pharmaceutical Expand Sugardown Licensing Agreement To Japan; Increases Number Of Asian Countries To 16 3/17/2015 1:06:05 PM
Boston Therapeutics, Inc. ' Hong Kong Affiliate Receives Department Of Health Certificate To Initiate SUGARDOWN(R) Clinical Trial 1/28/2015 12:29:51 PM